How Sweet It Is: Diagnostic Clinical And Experimental Glycoproteomics
Funder
National Health and Medical Research Council
Funding Amount
$473,477.00
Summary
Most human proteins are modified by the addition of complex sugar groups, which are important for the correct function of these key biological molecules. This fellowship will develop a suite of robust mass spectrometry glycoproteomic analytics for use in conjunction with clinical cohorts, model systems and in vitro biochemistry to investigate fundamental aspects controlling N-glycosylation in disease and translation to clinical diagnostics.
The pathology of many acute and chronic diseases associated with the inappropriate activation of genetically encoded programmed cell death pathways, such as sepsis, stroke, diabetes and neurodegeneration, is linked to detrimental inflammation. This project will accurately define at the molecular level how programmed cell death triggers inflammatory responses, and use this knowledge to test novel and next-generation therapeutic strategies in inflammatory-driven diseases.
Development And Plasticity Of The Visual Cortex: An Anatomical And Functional Study
Funder
National Health and Medical Research Council
Funding Amount
$420,872.00
Summary
Much of the human brain is devoted to vision, which requires the integrated activity of many interconnected areas of the cerebral cortex. Damage to these areas is a relatively common complication of preterm delivery and- or perinatal conditions including trauma and infection. The aim of this project is to investigate the way in which the multiple visual areas of the brain develop and become 'wired' together, and determine how the brain can successfully compensate for damage to these areas.
During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes, Alzheimer’s and Parkinson's. This research program will reveal how the body deactivates inflammasomes – protein complexes at the heart of inflammation and disease – so we can design better drugs for treating patients with inflammation-driven disease.
Cell death is a normal process that permits the growth and defense of our vital tissues. One kind of cell death, necroptosis, is characterised by the swelling and bursting of cells, triggering inflammation. Necroptosis is a key feature of illnesses ranging from colitis to arthritis, and contributes to the brain and heart damage that follows strokes and heart attacks. Understanding necroptotic cell death will pave the way for new therapies for those who suffer from these devastating conditions.
Identification Of Novel Targeted Therapies For JAK2-driven Leukemogenesis
Funder
National Health and Medical Research Council
Funding Amount
$392,717.00
Summary
Many leukemias are caused by particular signalling molecules becoming too active in blood cells. My research focusses on the molecules that are required by leukemic cells for their growth and survival. I will use mice that are prone to developing leukemia to study how these leukemias can be treated with drugs that block specific molecules. My goal is to discover new ways to treat leukemias that work better and have fewer side effects than current treatments.
Analysis Of Apoptotic Pathways To Develop Better Therapies For Unresponsive Cancers.
Funder
National Health and Medical Research Council
Funding Amount
$130,807.00
Summary
Tight control of the balance between cellular survival and death is important for normal development and to avoid numerous diseases. Inappropriate survival of precancerous cells can contribute to oncogenesis. Anti-cancer therapies act by inducing a cellular self-destruct program in tumour cells, and blocks in pathways controlling this process can lead to resistance to anti-cancer treatments. Defining cell death pathways will enable the development of better therapies for incurable cancers.
The Search For Novel Therapeutic Targets For The Treatment Of Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Chronic pain is very common, with one in five Australians suffering long-term pain that is serious enough to cause disability. It is extraordinarily difficult to treat. Medicines used to treat normal pain symptoms are usually ineffective on chronic pain patients because the cause of the pain is different. The aim of this project is to identify new drug targets in the spinal cord that are specific for chronic pain so we can develop new medicines to reverse the symptoms safely and effectively.